We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

HBM Healthcare Investments AG

HBM Partners

Cormorant Asset Management

SR One

Wellington Management

Novartis Venture Fund

OrbiMed

Pontifax

Samsung Securities

Medicxi

3B Future Health Fund

SICAR

Windham Venture Partners

Fore Biotherapeutics

We are excited to be presenting a poster at #AACR24 next week:
Abstract #:4609 “Plixorafenib (plixo) synergizes with MEK inhibitors (MEKi) in MAPK pathway inhibition in BRAF V600 and non V600 alterations, with higher potency compared to early generation BRAFi and pan-RAFi”
https://lnkd.in/epDjVhJE
Members of the team, Drs Stacie Shepherd, Ted Everson, and Ping J., look forward to connecting with you there!

Today, FORE Bio named William R. Hinshaw as Chief Executive Officer. Bill’s extensive leadership experience in biotech and pharma companies, including the approvals of multiple oncology products and indications while at Novartis, will be key as FORE advances its ongoing Global Phase 2 FORTE study of plixorafenib.
Click here to read the full release https://lnkd.in/eaaZ7yfd

Today, FORE Bio announced that the Company will participate in the following investor conferences: 
·        Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will take place on Wednesday, February 14 from 8:00 a.m. – 8:30 a.m. ET.
·        Evercore ISI’s 2024 Emerging Private Biotech Conference. The presentation will take place on Wednesday, February 28 from 1:05 p.m. – 1:35 p.m. ET.
Please email Forebio@argotpartners.com to request a 1:1 meeting with management.

We wish our team and our partners around the world a very Happy Holiday season and a peaceful and prosperous New Year. #TeamFore

FORE Bio will be presenting at the 2023 RBC Capital Markets Private Company Conference on Thursday, December 14 at 8 a.m. ET. The company will also be hosting 1-on-1 meetings. Please email forebio@argotpartners.com to request a meeting.
https://lnkd.in/gST_nu7h

Fore Bio is a next-generation precision oncology company that utilizes its functional genomics platform to hyper-target therapies to unaddressed tumor mutations, providing patients with few therapeutic alternatives with new treatments tailored to them.

BIO:FORE

Fore Bio

Filings Not Available